CN111955740A - 一种用于缓解和治疗特应性皮炎的组合物及其应用 - Google Patents
一种用于缓解和治疗特应性皮炎的组合物及其应用 Download PDFInfo
- Publication number
- CN111955740A CN111955740A CN202010809764.0A CN202010809764A CN111955740A CN 111955740 A CN111955740 A CN 111955740A CN 202010809764 A CN202010809764 A CN 202010809764A CN 111955740 A CN111955740 A CN 111955740A
- Authority
- CN
- China
- Prior art keywords
- composition
- oligosaccharide
- atopic dermatitis
- fructo
- alleviating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 60
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 60
- 230000000694 effects Effects 0.000 claims abstract description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 45
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 44
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 44
- 239000006041 probiotic Substances 0.000 claims abstract description 40
- 235000018291 probiotics Nutrition 0.000 claims abstract description 40
- 241000254697 Lactobacillus rhamnosus HN001 Species 0.000 claims abstract description 27
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 26
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 25
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 6
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 43
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 43
- 229930003316 Vitamin D Natural products 0.000 claims description 22
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 22
- 235000019166 vitamin D Nutrition 0.000 claims description 22
- 239000011710 vitamin D Substances 0.000 claims description 22
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 22
- 229940046008 vitamin d Drugs 0.000 claims description 22
- 239000006188 syrup Substances 0.000 claims description 16
- 235000020357 syrup Nutrition 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000000047 product Substances 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 6
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 6
- 238000011033 desalting Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 108010093096 Immobilized Enzymes Proteins 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- 210000004911 serous fluid Anatomy 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 6
- 241000186000 Bifidobacterium Species 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 235000014655 lactic acid Nutrition 0.000 abstract description 3
- 239000004310 lactic acid Substances 0.000 abstract description 3
- 239000002207 metabolite Substances 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 239000000843 powder Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 230000000529 probiotic effect Effects 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000002156 mixing Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 102000003816 Interleukin-13 Human genes 0.000 description 3
- 108090000176 Interleukin-13 Proteins 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102220220001 rs188579132 Human genes 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
组别 | SCORAD(平均值),初始 | SCORAD(平均值),6周后 |
安慰剂 | 25.39 | 25.53 |
实施例3 | 24.83 | 17.36 |
对比例1 | 25.05 | 22.73 |
对比例2 | 24.46 | 18.94 |
C1 | C2 | C3 | C4 | D1 | D2 | D3 | D4 | |
0月 | 10.57 | 10.57 | 10.53 | 10.51 | 10.59 | 10.62 | 10.60 | 10.60 |
3月 | 10.59 | 10.62 | 10.45 | 10.46 | 10.59 | 10.57 | 10.51 | 10.41 |
6月 | 10.49 | 10.49 | 10.32 | 10.49 | 10.56 | 10.43 | 10.43 | 10.34 |
9月 | 10.41 | 10.25 | 10.43 | 10.30 | 10.44 | 10.18 | 10.49 | 10.32 |
12月 | 10.28 | 10.17 | 10.25 | 10.03 | 10.28 | 10.21 | 10.35 | 10.14 |
15月 | 10.36 | 9.95 | 10.23 | 10.02 | 10.27 | 10.14 | 10.38 | 10.11 |
18月 | 10.27 | 9.96 | 10.20 | 9.95 | 10.29 | 9.95 | 10.24 | 9.98 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010809764.0A CN111955740A (zh) | 2020-08-12 | 2020-08-12 | 一种用于缓解和治疗特应性皮炎的组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010809764.0A CN111955740A (zh) | 2020-08-12 | 2020-08-12 | 一种用于缓解和治疗特应性皮炎的组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111955740A true CN111955740A (zh) | 2020-11-20 |
Family
ID=73364311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010809764.0A Pending CN111955740A (zh) | 2020-08-12 | 2020-08-12 | 一种用于缓解和治疗特应性皮炎的组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111955740A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113413400A (zh) * | 2021-06-02 | 2021-09-21 | 广州市锦盛生物科技有限公司 | 用于治疗特应性皮炎的微生物复合制剂 |
CN114390897A (zh) * | 2021-10-29 | 2022-04-22 | 海普诺凯营养品有限公司 | 一种益生元和益生菌的组合物及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2581461A1 (en) * | 2011-10-14 | 2013-04-17 | GenMont Biotech Incorporation | Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases |
CA2783414A1 (en) * | 2012-07-22 | 2014-01-22 | Integral Medical Inc. | Probiotic composition |
CN106617091A (zh) * | 2016-11-08 | 2017-05-10 | 广东正当年生物科技有限公司 | 一种益生菌和益生元复合制剂 |
CN107468716A (zh) * | 2017-08-24 | 2017-12-15 | 北京亦贝安生物医药科技有限公司 | 一种益生菌和益生元复方制剂及其加工方法 |
CN108771072A (zh) * | 2018-04-25 | 2018-11-09 | 深圳市多微生保健食品有限公司 | 一种益生菌组合物及婴幼儿益生菌固体饮料 |
CN109498660A (zh) * | 2018-11-23 | 2019-03-22 | 江南大学 | 一种能够缓解特应性皮炎的植物乳杆菌ccfm8610的应用 |
CN110432494A (zh) * | 2018-05-03 | 2019-11-12 | 广州普维君健药业有限公司 | 防治婴幼儿过敏性湿疹和/或腹泻的益生菌组合物和应用 |
CN111264879A (zh) * | 2020-01-21 | 2020-06-12 | 广东量子高科微生态医疗有限公司 | 一种合生元及其应用 |
-
2020
- 2020-08-12 CN CN202010809764.0A patent/CN111955740A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2581461A1 (en) * | 2011-10-14 | 2013-04-17 | GenMont Biotech Incorporation | Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases |
CA2783414A1 (en) * | 2012-07-22 | 2014-01-22 | Integral Medical Inc. | Probiotic composition |
CN106617091A (zh) * | 2016-11-08 | 2017-05-10 | 广东正当年生物科技有限公司 | 一种益生菌和益生元复合制剂 |
CN107468716A (zh) * | 2017-08-24 | 2017-12-15 | 北京亦贝安生物医药科技有限公司 | 一种益生菌和益生元复方制剂及其加工方法 |
CN108771072A (zh) * | 2018-04-25 | 2018-11-09 | 深圳市多微生保健食品有限公司 | 一种益生菌组合物及婴幼儿益生菌固体饮料 |
CN110432494A (zh) * | 2018-05-03 | 2019-11-12 | 广州普维君健药业有限公司 | 防治婴幼儿过敏性湿疹和/或腹泻的益生菌组合物和应用 |
CN109498660A (zh) * | 2018-11-23 | 2019-03-22 | 江南大学 | 一种能够缓解特应性皮炎的植物乳杆菌ccfm8610的应用 |
CN111264879A (zh) * | 2020-01-21 | 2020-06-12 | 广东量子高科微生态医疗有限公司 | 一种合生元及其应用 |
Non-Patent Citations (2)
Title |
---|
王磊等: "益生菌与过敏性疾病的预防和治疗进展", 《中国药事》 * |
郑轶武: "《医生必读 过敏性疾病前沿》", 31 March 2019, 广东科技出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113413400A (zh) * | 2021-06-02 | 2021-09-21 | 广州市锦盛生物科技有限公司 | 用于治疗特应性皮炎的微生物复合制剂 |
CN114390897A (zh) * | 2021-10-29 | 2022-04-22 | 海普诺凯营养品有限公司 | 一种益生元和益生菌的组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Markowiak et al. | Effects of probiotics, prebiotics, and synbiotics on human health | |
Thomas et al. | Probiotics and prebiotics in pediatrics | |
JP6271571B2 (ja) | 腸内微生物叢の平衡を保つための組成物、該組成物の製法、および、該組成物の利用 | |
JP6923741B2 (ja) | 消化器の健康、体重管理、免疫の強化および健康の改善のためのマルチ繊維プレバイオティクス組成物 | |
US20100166721A1 (en) | Probotic compositions and uses thereof | |
US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
CN111528479A (zh) | 一种缓解特应性皮炎功能的益生菌和益生元组合物及应用 | |
CN112056399A (zh) | 一种增强免疫力的益生菌组合物及其应用 | |
EP4245309A1 (en) | Composition containing bifidobacterium lactis and human milk oligosaccharides and application thereof | |
CN111955740A (zh) | 一种用于缓解和治疗特应性皮炎的组合物及其应用 | |
CN111955741B (zh) | 一种用于体重控制的组合物及其应用 | |
CN108077823A (zh) | 孕妇用免疫调节组合物及其应用 | |
CN112273657A (zh) | 用于预防或改善过敏性疾病的益生菌组合物、制法和应用 | |
CN116981468A (zh) | 益生菌组合物以及使用其促进儿童生长和社交功能的方法 | |
CN114452308A (zh) | 一种益生菌保护剂及其制备的微生态制剂和用途 | |
CN113750113A (zh) | 一种益生菌和益生元的组合物及其应用 | |
CN110313599A (zh) | 一种降尿酸果冻及其制备方法 | |
WO2017159647A1 (ja) | フィーカリバクテリウム属細菌増殖剤 | |
EP3958844A1 (en) | Microbial compositions and methods for greater tolerability and prolonged shelf life | |
CN114933984B (zh) | 一种促进体内塑化剂及重金属排出的益生菌益生元复合组合物及其制备方法 | |
CN110448569B (zh) | 一种具有止泻功效的组合物及其制备方法和其应用 | |
WO2014134830A1 (zh) | 可食用组合物以及包含其的食品、该食品的制备方法 | |
CN106974940B (zh) | 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用 | |
YASMIN et al. | The Effect of Honey Supplementation on Plasma Levels of Short Chain Fatty Acids in Healthy Infants | |
Hara et al. | In vivo evaluation of holocellulose and cellulose isolated from kumaizasa (Sasa senanensis) powder on bowel movements in rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 529040 No.133, Gaoxin West Road, Gaoxin District, Jiangmen City, Guangdong Province Applicant after: Smart Pharmaceutical Technology Co.,Ltd. Address before: 529040 No.133, Gaoxin West Road, Gaoxin District, Jiangmen City, Guangdong Province Applicant before: QUANTUM HI-TECH(CHINA) BIOLOGICAL Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220607 Address after: 529040 No. 133, Gaoxin West Road, Gaoxin District, Jiangmen City, Guangdong Province (one address with multiple photos) Applicant after: Quantum hi tech (Guangdong) biology Co.,Ltd. Address before: 529040 No.133, Gaoxin West Road, Gaoxin District, Jiangmen City, Guangdong Province Applicant before: Smart Pharmaceutical Technology Co.,Ltd. |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201120 |